In continuation with its commitment to make medicines affordable and accessible, particularly in anti-cancer medication, in May 2012, Cipla announced a dramatic price cut in three major anti-cancer drugs – Sorafenib (SORANIB), Gefitinib (GEFTICIP) and Temozolomide (TEMOSIDE).
| The revised prices for the selected products are stated below | |||||
| Indication | Molecule | Brand name | Current price (in Rs.) | Revised price (in Rs.) | Reduction (in Rs) |
| Lung cancer (Metastatic non-small cell cancer) | Erlotinib | ERLOCIP 150 30 tablets |
27,000 | 9,900 | 17,100 |
| ERLOCIP 150 10 tablets |
10,000 | 3,700 | 6,300 | ||
| ERLOCIP 100 30 tablets |
18,000 | 6,600 | 11,400 | ||
| Breast cancer, lung cancer (Non-small cell & small cell), head & neck cancer, gastric cancer, bladder cancer | Docetaxel | DOCETAX 20 mg | 3,300 | 1,650 | 1,650 |
| DOCETAX 80 mg | 10,000 | 5,000 | 5,000 | ||
| DOCETAX 120 mg | 14,000 | 7,000 | 7,000 | ||
| Metastatic breast cancer, metastatic colorectal cancer, metastatic colon cancer | Capecitabine | CAPEGARD 500 mg 10 tablets |
1,200 | 600 | 600 |
Following the overwhelming response on the price cut received from the patients and their families and doctors, Cipla is now announcing another breakthrough price reduction in three additional anti-cancer drugs – Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are for the treatment of lung and pancreatic cancer, breast cancer, head & neck cancer, gastric cancer, bladder, colorectal and colon cancers.
“Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and Malaria to now include cancer, not only in India but globally,” announced Dr YK Hamied, Chairman and Managing Director, Cipla.
EP News Bureau